<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02755259</url>
  </required_header>
  <id_info>
    <org_study_id>KEK-ZH-2016-00089</org_study_id>
    <nct_id>NCT02755259</nct_id>
  </id_info>
  <brief_title>Acute Hemodynamic Effect of Acetazolamide in Pulmonary Hypertension</brief_title>
  <acronym>AcuteAZA</acronym>
  <official_title>Acute Hemodynamic Effect of Acetazolamide in Pulmonary Hypertension</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Zurich</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Zurich</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To study the acute effect of acetazolamide (AZA) on pulmonary hemodynamics in patients with
      pulmonary hypertension (PH) undergoing clinically indicated right heart catheterisation
      (RHC).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Pulmonary hypertension (PH) of various etiologies causes dyspnea, impairs exercise
      performance and is associated with reduced quality of life (QoL) and survival. Treatment
      options include therapy for any underlying causes, pulmonary vasodilator drugs, oxygen and,
      in selected cases, pulmonary endarterectomy or lung transplantation. Unfortunately, PH
      specific drugs are expensive, associated with side effects and even combined pharmacological
      treatment is often not sufficient to achieve clinical benefits. Therefore, novel therapeutic
      drugs are needed. The investigators have recently demonstrated that sleep related breathing
      disorders, which are common in PH patients, can be improved by both nocturnal oxygen therapy
      and acetazolamide (AZA). AZA is a carbonic anhydrase (CA) inhibitor that acts as a
      respiratory stimulant thereby improving oxygenation and possibly PH. There are even data
      suggesting that CA-inhibitors have a direct pulmonary vasodilator effect. However, the
      potential role of AZA in the treatment of PH has not been conclusively studied. Therefore,
      the purpose of the current project is to investigate, the acute hemodynamic clinical effects
      of AZA in PH patients.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">January 1, 2017</start_date>
  <completion_date type="Actual">April 5, 2019</completion_date>
  <primary_completion_date type="Actual">April 5, 2019</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Pulmonary vascular resistance (PVR) AZA vs. Placebo (rest)</measure>
    <time_frame>60 minutes</time_frame>
    <description>At the end of phase at rest</description>
  </primary_outcome>
  <primary_outcome>
    <measure>PVR AZA vs. Placebo (exercise)</measure>
    <time_frame>60 minutes</time_frame>
    <description>At the end of phase at exercise</description>
  </primary_outcome>
  <primary_outcome>
    <measure>PVR AZA vs. Placebo (hypoxia)</measure>
    <time_frame>60 minutes</time_frame>
    <description>At the end of phase under hypoxia</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>partial pressure of the oxygen</measure>
    <time_frame>60 minutes</time_frame>
    <description>At the end of each phase (rest, exercise and hypoxia)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Oxygen uptake</measure>
    <time_frame>15 minutes</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>minute ventilation</measure>
    <time_frame>15 minutes</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>arterial oxygenation</measure>
    <time_frame>60 minutes</time_frame>
    <description>At the end of each phase (rest, exercise and hypoxia)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>tissue oxygenation</measure>
    <time_frame>60 minutes</time_frame>
    <description>At the end of each phase (rest, exercise and hypoxia)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>mean pulmonary arterial pressure</measure>
    <time_frame>60 minutes</time_frame>
    <description>At the end of each phase (rest, exercise and hypoxia)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>cardiac output</measure>
    <time_frame>60 minutes</time_frame>
    <description>At the end of each phase (rest, exercise and hypoxia)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>cardiac index</measure>
    <time_frame>60 minutes</time_frame>
    <description>At the end of each phase (rest, exercise and hypoxia)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>pulmonary wedge pressure</measure>
    <time_frame>60 minutes</time_frame>
    <description>At the end of each phase (rest, exercise and hypoxia)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Borg scale dyspnea and leg effort</measure>
    <time_frame>15 minutes</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">33</enrollment>
  <condition>Hypertension, Pulmonary</condition>
  <arm_group>
    <arm_group_label>Acetazolamide</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Diamox 500mg i.v. (1x)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo Saline injection (1x)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Acetazolamide</intervention_name>
    <arm_group_label>Acetazolamide</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  All patients undergoing RHC for a clinical indication and who are diagnosed with
             precapillary PH (mPAP ≥25 mmHg, pulmonary wedge pressure (PAWP) ≤15mmHg)

        Exclusion Criteria:

          -  Patients in whom a RHC is clinically not indicated

          -  pregnant women

          -  PH in left heart disease or with more than mild chronic obstructive pulmonary disease
             or restrictive lung disease.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Silvia Ulrich, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>UniversityHospital Zurich</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University Hospital Zurich</name>
      <address>
        <city>Zurich</city>
        <zip>8091</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Switzerland</country>
  </location_countries>
  <verification_date>August 2019</verification_date>
  <study_first_submitted>March 24, 2016</study_first_submitted>
  <study_first_submitted_qc>April 25, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 28, 2016</study_first_posted>
  <last_update_submitted>August 12, 2019</last_update_submitted>
  <last_update_submitted_qc>August 12, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">August 13, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Acetazolamide</keyword>
  <keyword>Hemodynamics</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypertension, Pulmonary</mesh_term>
    <mesh_term>Hypertension</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Acetazolamide</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

